A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

NCT03486392 on ClinicalTrials.gov · last registry update 2020-02-05

An unusually large phase 2: 474 participants, more than double the 110 typical for the stage. The sponsor logged completion for 8 March 2019. Primary outcome, as filed: Percent Change From Baseline in Body Weight at Week 26. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Janssen Research & Development, LLC
Sponsor type: Industry
Enrollment: 474
Started: 2018-03-26
Primary completion: 2019-03-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight at Week 26

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.